OKUR (OnKure Therapeutics) ROCE % : -42.94% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OnKure Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -42.94%.

OnKure Therapeutics ROCE % Historical Data

The historical data trend for OnKure Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics ROCE % Chart

OnKure Therapeutics Annual Data

Trend

Dec22

Dec23

ROCE %

-284.65

-189.86

OnKure Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial			-	296.85	-165.84	-358.82	-42.94

OnKure Therapeutics ROCE % Calculation

OnKure Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.934	/	( ( (15.999 - 5.542)	+	(35.734 - 7.285) )	/ 2 )
	=	-36.934	/	( (10.457	+	28.449)	/ 2 )
	=	-36.934	/	19.453
	=	-189.86 %

OnKure Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-18.656	/	( ( (25.473 - 12.984)	+	(77.645 - 3.248) )	/ 2 )
	=	-18.656	/	( ( 12.489	+	74.397 )	/ 2 )
	=	-18.656	/	43.443
	=	-42.94 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

OnKure Therapeutics (NAS:OKUR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OnKure Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of OnKure Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OnKure Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301

Website

https://www.onkuretherapeutics.com

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.